DrugPatentWatch Database Preview
Litigation Details for Uniloc USA, Inc. v. Apple Inc. (N.D. Cal. 2018)
» See Plans and Pricing
Uniloc USA, Inc. v. Apple Inc. (N.D. Cal. 2018)
| Docket | Start Trial | Date Filed | 2018-01-16 |
| Court | District Court, N.D. California | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | William Haskell Alsup |
| Jury Demand | Both | Referred To | Joseph Spero |
| Parties | UNILOC USA, INC. | ||
| Patents | 6,020,001 | ||
| Attorneys | Michael Thomas Pieja | ||
| Firms | Goldman Ismail Tomaselli Brennan & Baum LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Uniloc USA, Inc. v. Apple Inc.
The small molecule drug covered by the patent cited in this case is Start Trial .
Details for Uniloc USA, Inc. v. Apple Inc. (N.D. Cal. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-11-11 | 217 | Intervene | Filed 11/12/20 Page 6 of 20 1 OTHER AUTHORITIES 2 Abby Rives, Fortress Patent Fight Shows Abusive…24 amounts paid to license Uniloc’s patents. Because a patent grants its owner exclusive rights, Uniloc…use its patents. See F.T.C. v. Actavis, Inc., 570 U.S. 136, 147 (2013) (“[A] 26 valid patent excludes… ownership of the patents-in-suit and thus its right to assert those patents against individuals and… Uniloc’s patent assertion activities because it “is 26 one of the most active [patent assertion | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
